Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

731149.pdf (3.6 MB)

Document type

Article

Version

Published version

Publication date

2022-03-18

Publication license

cc-by-nc (c) Torres Martí, Antoni et al., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/198626

Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.2147/CEOR.S329494

Abstract

Purpose: Complicated skin and soft tissue infections (cSSTI) are associated with high healthcare resource use and costs. The emergency nature of cSSTI hospitalizations requires starting immediate empiric intravenous (IV) antibiotic treatment, making the appropriate choice of initial antibiotic therapy crucial. Patients and methods: The use of ceftaroline fosamil (CFT) as an alternative to other IV antibiotic therapies for the empiric treatment of hospitalized adults with cSSTI (vancomycin, linezolid, daptomycin, cloxacillin, tedizolid) was evaluated through cost consequences analysis. The model structure was a decision tree accounting for four different pathways: patients demonstrating early response (ER) either discharged early (with oral antibiotic) or remaining in hospital to continue the initial therapy; non-responders either remaining on the initial IV therapy or switching to a second-line antibiotic. The model perspective was the Spanish National Health System. Results: CFT resulted in average percentage of patients discharged early (PDE) of 24.6% (CI 19.49-30.2%) with average total cost per patient of 6763 ( 6268- 7219). Vancomycin, linezolid, daptomycin and tedizolid resulted in average PDE of 22% (17.34-27.09%), 26.4% (20.5-32.32%), 28.6% (22.08-35.79%) and 26.5% (20.39-33.25%), respectively, for a total cost per patient of 6,619 ( 5,902- 6,929), 6,394 ( 5,881- 6,904), 6,855 ( 5,800- 7,410) and 7,173 ( 6,608- 7,763), respectively. Key model drivers were ER and antibiotic treatment duration, with hospital costs accounting for over 83% of the total expenditures. Conclusion: Given its clinical and safety profile, CFT is an acceptable choice for cSSTI empiric therapy providing comparable ER and costs to other relevant antibiotic options.

Subject

Malalties de la pell, Complicacions (Medicina), Antibiòtics betalactàmics, Malalts hospitalitzats, Anàlisi econòmica, Espanya

Subject (English)

Skin diseases, Complications (Medicine), Beta lactam antibiotics, Hospital patients, Economic analysis, Spain

Citation

Collections

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citation

TORRES MARTÍ, Antoni, et al. Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System. Clinicoeconomics and Outcomes Research. 2022. Vol. 14, num. 149-161. ISSN 1178-6981. [consulted: 15 of August of 2026]. Available at: https://hdl.handle.net/2445/198626

Export metadata

JSON - METS

Share record